Effect of stereotactic hematoma puncture aspiration combined with edaravone in treatment of patients with cerebral hemorrhage in Neurosurgery Intensive Care Unit

Objective To explore the effect of stereotactic hematoma puncture aspiration (SHPS) combined with edaravone in the treatment of patients with cerebral hemorrhage in the Neurosurgery Intensive Care Unit (NICU).

Methods A total of 98 patients with cerebral hemorrhage in NICU were divided into experimental group and control group by drawing lots, with 49 cases in each group. The control group was treated with SHPS and conventional therapy, while the experimental group was treated with edaravone on the basis of the control group. The clinical efficacy, the quality of lifethe National Institute of Health Stroke Scale (NIHSS) score, the Ability of Daily Living (ADL) score and the China Stroke Scale (CSS) score, glucose and lipid metabolism indicatorsjugular venous oxygen saturation (SjvO₂), arteriovenous lactate (A-VLac) and arteriovenous glucose (A-VGlu), inflammatory factorsinterleukin-8 (IL-8), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)levels as well as incidence of complications were compared between the two groups.

Results The total effective rate of the experimental group was 91.84%, which was significantly higher than 77.55% of the control group (P < 0.05). After treatment, the NIHSS score and CSS score of the experimental group were significantly lower than those of the control group, while the ADL score was significantly higher than that of the control group (P < 0.05). After treatment, the SjvO₂ level in the experimental group was significantly higher than that in the control group, while the levels of A-VGlu and A-VLac were significantly lower than those in the control group (P < 0.05). After treatment, the IL-8, IL-6 and TNF-α levels in the experimental group were significantly lower than those in the control group (P < 0.05). The incidence of complications in the experimental group was 12.24%, which was significantly lower than 30.61% in the control group (P < 0.05).

Conclusion The combination of SHPS and edaravone can reinforce the clinical efficacy of patients with cerebral hemorrhage in NICU, improve neurological function, and reduce the incidence of postoperative complications.